Pharmacy

Piramal Healthcare Ltd (PHL), hs recently announced the Quarter 4 (Q4) and year ending results for the Financial Year (FY)2011.

For the continuing businesses, total operating income for the quarter was up by 62 per cent to RS. 689.1 crore. The total operating income includes RS. 130 crore towards income from investments. Including this income, the operating profit for the quarter was at RS. 263.1 crore against RS.58.5 crore for Q4 FY 2010. Net profit for the quarter was RS.201.8 crore and Earnings per Share (EPS) was RS. 9.0 Per share. During the quarter the Piramal facilities at Ahemadabad, Ennore and Canada were audited by 14 out of the top 20 global innovator companies. Revenues from Piramal Critical Care business have grown by 31 per cent to RS.116.0 crore against? 88.4 crore in Q4FY2010. Sevoflurane market share for PHL in US has increased from 14 per cent as on March 2010 to 20 per cent in March 2011. PHL will expand Sevoflurane sales to Europe with registration applied for in 26 European Union (EU) countries. Over-The-Counter (OTC) & Ophthalmology business recorded impressive growth of 27 per cent over Q4FY2010 to RS. 67.6 crore.

For the continuing businesses, total operating income for the year was up by 27 per cent to RS. 2,009.2 crore. The total operating income includes RS. 335.8 crore towards income from investments. Including this income, the operating profit for the year was at RS. 379.0 crore against RS. 139.2 crore for FY2010. Net profit for the year was RS.12, 735.0 crore and EPS was RS. 567.1 Per share.